Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지

General Pharmacology of CJC-50100, a Recombinant Hepatitis B Virus Surface Antigen

유전자 재조합 B형 간염 바이러스 표면 항원, CJC-50100의 일반약리작용

  • 정성학 (제일제당(주)종합기술원) ;
  • 최재묵 (제일제당(주)종합기술원) ;
  • 이남중 (제일제당(주)종합기술원) ;
  • 전형수 (제일제당(주)종합기술원) ;
  • 김연희 (제일제당(주)종합기술원) ;
  • 김재승 (제일제당(주)종합기술원) ;
  • 하석훈 (제일제당(주)종합기술원) ;
  • 김영훈 (제일제당(주)종합기술원) ;
  • 이나경 (제일제당(주)종합기술원)
  • Published : 2001.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

CJC-50100 is a recombinant hepatitis B virus surface antigen (HBsAg) expressed in yeast. The general pharmacological properties of CJC-50100 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses were 0.33~33.3 $\mu$g/kg i.m. for mice and rats and 3.3~9.9 $\mu$g/kg i.v. for dogs. The concentrations of 0.002~0.02 $\mu$g/ml were used for the assay with guinea pig ileum. Intramuscular administration of CJC-50100 at the doses did not alter general behavior and the responses for central nervous system, smooth muscle, gastrointestinal system, cardiovascular and respiratory system, and water and electrolytes excretion. In summary, CJC-50100 had no pharmacological effect in these studies even up to the 100-fold of the expected clinical dose, 20 $\mu$g/man/60 kg.

Keywords